Clinical Biomarkers and Prognosis in Taiwanese Patients with Non-Small Cell Lung Cancer (NSCLC)


Introduction: Lung cancer is the leading cause of cancer death worldwide with poor survival rates. However, the prognostic factors for survival of patients with lung cancer are not well-established. In this study, we examined the impact of routine laboratory biomarkers and traditional factors on survival of patients with non-small cell lung cancer (NSCLC). Method: Secondary data analysis was conducted from a retrospective study of 404 patients with newly diag-nosed lung cancer in 2005-2007 in Taiwan. There were eight routine laboratory biomarkers and eight traditional factors investigated in the analyses. Cox proportional hazards model was used to assess the hazard ratios for the association between risk factors and patient overall survival. The Kaplan-Meier method was used to compare survival curves for each prognostic indicator. Results: High WBC counts (HR = 1.798, 95%CI: 1.225 - 2.639), low Hgb level (HR = 1.437, 95%CI: 1.085 - 1.903), and low serum albumin level (HR = 2.049, 95%CI: 1.376 - 3.052) were significant laboratory prognostic biomarkers for poor NSCLC survival. Additionally we confirmed the traditional prognostic factors for poor overall survival among NSCLC patients, including older age, comorbidity conditions, advanced cancer stage, and non-surgical treatment. Conclusions: This study identified three available laboratory biomarkers, high WBC counts, low Hgb level, and low serum albumin level, to be significant prognostic factors for poorer overall survival in NSCLC patients. Further prognostic evaluation studies are warranted to compare different ethnic groups on the prognostic values of these clinical parameters in NSCLC survival outcomes. These identified prognostic biomarkers should be included in early risk screening of hospitalized lung cancer patient population.

Share and Cite:

Y. Li, Y. Chen, L. Chang, M. Hendryx and J. Luo, "Clinical Biomarkers and Prognosis in Taiwanese Patients with Non-Small Cell Lung Cancer (NSCLC)," Journal of Cancer Therapy, Vol. 3 No. 4A, 2012, pp. 412-423. doi: 10.4236/jct.2012.324054.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun, “Cancer Statistics, 2009,” CA—A Cancer Journal for Clinicians, Vol. 59, No. 4, 2009, pp. 225-249. doi:10.3322/caac.20006
[2] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA—A Cancer Journal for Clinicians, Vol. 61, No. 6, 2011, pp. 69-90. doi:10.3322/caac.20107
[3] C. L. B. Ott, N. Ratna, R. Prayag, Z. Nugent, K. Badiani and S. Navaratnam, “Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba,” Current Oncology, Vol. 18, No. 5, 2011, pp. e238-e242.
[4] E. Quoix, V. Westeel, G. Zalcman and B. Milleron, “Chemotherapy in Elderly Patients with Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 74, No. 3, 2011, pp. 364-368. doi:10.1016/j.lungcan.2011.06.006
[5] W. D. Wei, Z. S. Wen, X. D. Su, P. Lin, T. H. Rong and L. K. Chen, “Multivariate Survival Analysis of 899 Patients with Non-Small Cell Lung Cancer after Complete Resection,” Cancer, Vol. 26, No. 11, 2007, pp. 1231-1236.
[6] K. Hotta, Y. Fujiwara, K. Kiura, N. Takigawa, M. Tabata, H. Ueoka and M. Tanimoto, “Relationship between Response and Survival in More than 50,000 Patients with Advanced Non-Small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials,” Journal of Thoracic Oncology, Vol. 2, 2007, pp. 402-407. doi:10.1097/01.JTO.0000268673.95119.c7
[7] J. L. Port, M. S. Kent, R. J. Korst, D. Libby, M. Pasmantier and N. K. Altorki, “Tumor Size Predicts Survival within Stage IA Non-Small Cell Lung Cancer,” Chest, Vol. 124, No. 5, 2003, pp. 1828-1833. doi:10.1378/chest.124.5.1828
[8] E. F. Patz Jr., S. Rossi, D. H. Harpole Jr., J. E. Herndon and P. C. Goodman, “Correlation of Tumor Size and Survival in Patients with Stage IA Non-Small Cell Lung Cancer,” Chest, Vol. 117, 2000, pp. 1568-1571. doi:10.1378/chest.117.6.1568
[9] L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, K. Dagg and H. R. Scott, “A Prospective Longitudinal Study of Performance Status, an Inflammation-Based Score (GPS) and Survival in Patients with Inoperable Non-Small-Cell Lung Cancer,” British Journal of Cancer, Vol. 92, 2005, pp. 1834-1836. doi:10.1038/sj.bjc.6602591
[10] H. R. Scott, D. C. McMillan, L. M. Forrest, D. J. Brown, C. S. McArdle and R. Milroy, “The Systemic Inflammatory Response, Weight Loss, Performance Status and Survival in Patients with Inoperable Non-Small Cell Lung Cancer,” British Journal of Cancer, Vol. 87, No. 3, 2002, pp. 264-267. doi:10.1038/sj.bjc.6600466
[11] M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding and C. P. Belani, “Skin Rash and Good Performance Status Predict Improved Survival with Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer,” Annals of Oncology, Vol. 16, No. 5, 2005, pp. 780-785. doi:10.1093/annonc/mdi157
[12] T. Maeda, H. Ueoka, M. Tabata, K. Kiura, T. Shibayama, K. Gemba, N. Takigawa, A. Hiraki, H. Katayama and M. Harada, “Prognostic Factors in Advanced Non-Small Cell Lung Cancer: Elevated Serum Levels of Neuron Specific Enolase Indicate Poor Prognosis,” Japanese Journal of Clinical Oncology, Vol. 30, No. 12, 2000, pp. 534-541. doi:10.1093/jjco/hyd139
[13] S. J. Mandrekar, S. E. Schild, S. L. Hillman, K. L. Allen, R. S. Marks, J. A. Mailliard, J. E. Krook, A. W. Maksymiuk, K. Chansky, K. Kelly, A. A. Adjei and J. R. Jett, “A Prognostic Model for Advanced Stage Nonsmall Cell Lung Cancer. Pooled Analysis of North Central Cancer Treatment Group Trials,” Cancer, Vol. 107, No. 4, 2006, pp. 781-792. doi:10.1002/cncr.22049
[14] C. W. Francis, A. Blinc, S. Lee and C. Cox, “Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots,” Ultrasound in Medicine & Biology, Vol. 21, No. 3, 1995, pp. 419-424. doi:10.1016/0301-5629(94)00119-X
[15] L. R. Zacharski, M. Z. Wojtukiewicz, V. Costantini, D. L. Ornstein and V. A. Memoli, “Pathways of Coagulation/Fibrinolysis Activation in Malignancy,” Semin Thromb Hemost, Vol. 18, No. 1, 1992, pp. 104-116. doi:10.1055/s-2007-1002415
[16] K. R. Meehan, L. R. Zacharski, T. E. Moritz and F. R. Rickles, “Pretreatment Fibrinogen Levels Are Associated with Response to Chemotherapy in Patients with Small Cell Carcinoma of the Lung: Department of Veterans Affairs Cooperative Study 188,” American Journal of Hematology, Vol. 49, 1995, pp. 143-148. doi:10.1002/ajh.2830490208
[17] O. Taguchi, E. C. Gabazza, H. Yasui, T. Kobayashi, M. Yoshida and H. Kobayashi, “Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer,” Thorax, Vol. 52, No. 6, 1997, pp. 563-565. doi:10.1136/thx.52.6.563
[18] M. Z. Wojtukiewicz, L. R. Zacharski, T. E. Moritz, K. Hur, R. L. Edwards and F. R. Rickles, “Prognostic Significance of Blood Coagulation Tests in Carcinoma of the Lung and Colon,” Blood Coagul Fibrinolysis, Vol. 3, No. 4, 1992, pp. 429-437.
[19] D. Ferrigno, G. Buccheri and I. Ricca, “Prognostic Significance of Blood Coagulation Tests in Lung Cancer,” European Respiratory Journal, Vol. 17, No. 4, 2001, pp. 667-673. doi:10.1183/09031936.01.17406670
[20] M. Paesmans, J. P. Sculier, P. Libert, G. Bureau, G. Dabouis, J. Thiriaux, J. Michel, O. Van Cutsem, R. Sergysels, P. Momme, et al., “Prognostic Factors for Survival in Advanced Non-Small-Cell Lung Cancer: Univariate and Multivariate Analyses Including Recursive Partitioning and Amalgamation Algorithms in 1052 Patients. The European Lung Cancer Working Party,” Journal of Clinical Oncology, Vol. 13, No. 5, 1995, pp. 1221-1230.
[21] J. S. Paddison, J. S. Temel, G. L. Fricchione and W. F. Pirl, “Using the Differential from Complete Blood Counts as a Biomarker of Fatigue in Advanced Non-Small-Cell Lung Cancer: An Exploratory Analysis,” Palliat Support Care, Vol. 7, No. 2, 2009, pp. 213-217. doi:10.1017/S1478951509000273
[22] D. Ferrigno and G. Buccheri, “Hematologic Counts and Clinical Correlates in 1201 Newly Diagnosed Lung Cancer Patients,” Monaldi Archives for Chest Disease, Vol. 59, No. 3, 2003, pp. 193-198.
[23] T. Win, L. Sharples, A. M. Groves, A. J. Ritchie, F. C. Wells and C. M. Laroche, “Predicting Survival in Potentially Curable Lung Cancer Patients,” Lung, Vol. 186, No. 2, 2008, pp. 97-102. doi:10.1007/s00408-007-9067-1
[24] F. Tas, A. Aydiner, E. Topuz, H. Camlica, P. Saip and Y. Eralp, “Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung Cancer,” Acta Oncologica, Vol. 38, No. 8, 1999, pp. 1011-1015. doi:10.1080/028418699432275
[25] S. L. Vanhees, R. Paridaens and J. F. Vansteenkiste, “Syndrome of Inappropriate Antidiuretic Hormone Associated with Chemotherapy-Induced Tumour Lysis in Small-Cell Lung Cancer: Case Report and Literature Review,” Annals of Oncology, Vol. 11, 2000, pp. 1061-1065. doi:10.1023/A:1008369932384
[26] O. Hansen, P. Sorensen and K. H. Hansen, “The Occurrence of Hyponatremia in SCLC and the Influence on Prognosis: A Retrospective Study of 453 Patients Treated in a single Institution in a 10-Year Period,” Lung Cancer, Vol. 68, No. 1, 2010, pp. 111-114. doi:10.1016/j.lungcan.2009.05.015
[27] N. S. Rawson and J. Peto, “An Overview of Prognostic Factors in Small Cell Lung Cancer. A Report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research,” British Journal of Cancer, Vol. 61, No. 4, 1990, pp. 597-604. doi:10.1038/bjc.1990.133
[28] J. Luo, Y. J. Chen and L. J. Chang, “Fasting Blood Glucose Level and Prognosis in Non-Small Cell Lung Cancer (NSCLC) Patients,” Lung Cancer, Vol. 76, No. 2, 2011, pp. 242-247. doi:10.1016/j.lungcan.2011.10.019
[29] M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis, E. T. McFadden and P. P. Carbone, “Toxicity and Response Criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, Vol. 5, No. 6, 1982, pp. 649-655. doi:10.1097/00000421-198212000-00014
[30] M. E. Charlson, P. Pompei, K. L. Ales and C. R. MacKenzie, “A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation,” Journal of Chronic Diseases, Vol. 40, No. 5, 1987, pp. 373-383. doi:10.1016/0021-9681(87)90171-8
[31] O. Birim, A. P. Kappetein and A. J. Bogers, “Charlson Comorbidity Index as a Predictor of Long-Term Outcome after Surgery for Nonsmall Cell Lung Cancer,” European Journal Cardio-Thoracic Surgery, Vol. 28, No. 5, 2005, pp. 759-762. doi:10.1016/j.ejcts.2005.06.046
[32] J. V. Corbett, “Laboratory Tests and Diagnostic Procedures with Nursing Diagnoses,” Pearson/Prentice Hall, Upper Saddle River, 2004.
[33] D. R. Cox and D. Oakes, “Analysis of Survival Data,” Chapman and Hall, London, 1984.
[34] S. Leij-Halfwerk, P. C. Dagnelie, J. W. van Den Berg, J. D. Wattimena, C. H. Hordijk-Luijk and J. P. Wilson, “Weight Loss and Elevated Gluconeogenesis from Alanine in Lung Cancer Patients,” American Journal of Clinical Nutrition, Vol. 71, 2000, pp. 583-589.
[35] H. Wertzel, H. Siebert, W. Lange, L. Swoboda, E. Graf and J. Hasse, “Results after Surgery in Stage-I Bronchogenic Carcinoma,” Journal of Thoracic and Cardiovascular Surgery, Vol. 46, 1998, pp. 365-369. doi:10.1055/s-2007-1010255
[36] R. R. Jennens, G. G. Giles and R. M. Fox, “Increasing Under Representation of Elderly Patients with Advanced Colorectal or Non-Small-Cell Lung Cancer in Chemotherapy Trials,” Internal Medicine Journal, Vol. 36, 2006, pp. 216-220. doi:10.1111/j.1445-5994.2006.01033.x
[37] C. Y. Wang, Y. S. Lin, C. Tzao, H. C. Lee, M. H. Huang, W. H. Hsu and H. S. Hsu, “Comparison of Charlson Comorbidity Index And Kaplan-Feinstein Index in Patients with Stage I Lung Cancer after Surgical Resection,” European Journal Cardio-Thoracic Surgery, Vol. 32, No. 6, 2007, pp. 877-881. doi:10.1016/j.ejcts.2007.09.008
[38] S. Firat, M. Bousamra, E. Gore and R. W. Byhardt, “Comorbidity and KPS Are Independent Prognostic Factors in Stage I Non-Small-Cell Lung Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 52, 2002, pp. 1047-1057.
[39] D. Moro-Sibilot, A. Aubert, S. Diab, S. Lantuejoul, P. Fourneret, E. Brambilla, C. Brambilla and P. Y. Brichon, “Comorbidities and Charlson Score in Resected Stage I nonsmall Cell Lung Cancer,” European Respiratory Journal, Vol. 26, No. 3, 2005, pp. 480-486. doi:10.1183/09031936.05.00146004
[40] A. Shankar, J. J. Wang, E. Rochtchina, M. C. Yu, R. Kefford and P. Mitchell, “Association between Circulating White Blood Cell Count and Cancer Mortality: A Population-Based Cohort Study,” Archives of Internal Medicine, Vol. 166, 2006, pp. 188-194. doi:10.1001/archinte.166.2.188
[41] L. M. Coussens and Z. Werb, “Inflammation and Cancer,” Nature, Vol. 420, No. 6917, 2002, pp. 860-867. doi:10.1038/nature01322
[42] F. Balkwill, “Cancer and the Chemokine Network,” Nature Reviews Cancer, Vol. 4, 2004, pp. 540-550. doi:10.1038/nrc1388
[43] F. Balkwill and L. M. Coussens, “Cancer: An Inflammatory Link,” Nature, Vol. 431, No. 7007, 2004, pp. 405-406. doi:10.1038/431405a
[44] E. Pikarsky, R. M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun and Y. Ben-Neriah, “NF-kappaB Functions as a Tumour Promoter in Inflammation-Associated Cancer,” Nature, Vol. 431, No. 7007, 2004, pp. 461-466. doi:10.1038/nature02924
[45] M. D. Brundage, D. Davies and W. J. Mackillop, “Prognostic Factors in Non-Small Cell Lung Cancer: A Decade of Progress,” Chest, Vol. 122, No. 3, 2002, pp. 1037-1057. doi:10.1378/chest.122.3.1037
[46] S. Sugiura, Y. Ando, H. Minami, M. Ando, S. Sakai and K. Shimokata, “Prognostic Value of Pleural Effusion in Patients with Non-Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 3, 1997, pp. 47-50.
[47] N. Takigawa, Y. Segawa, M. Okahara, Y. Maeda, I. Takata, M. Kataoka and M. Fujii, “Prognostic Factors for Patients with Advanced Non-Small Cell Lung Cancer: Univariate and Multivariate Analyses Including Recursive Partitioning and Amalgamation,” Lung Cancer, Vol. 15, No. 1, 1996, pp. 67-77. doi:10.1016/0169-5002(96)00571-5
[48] K. S. Albain, J. J. Crowley, M. LeBlanc and R. B. Livingston, “Survival Determinants in Extensive-Stage Non-Small-Cell Lung Cancer: The Southwest Oncology Group Experience,” Journal of Clinical Oncology, Vol. 9, No. 9, 1991, pp. 1618-1626.
[49] A. Phillips, A. G. Shaper and P. H. Whincup, “Association between Serum Albumin and Mortality from Cardiovascular Disease, Cancer, and Other Causes,” Lancet, Vol. 2, 1989, pp. 1434-1436. doi:10.1016/S0140-6736(89)92042-4
[50] B. R. Don and G. Kaysen, “Serum Albumin: Relationship to Inflammation and Nutrition,” Seminars in Dialysis, Vol. 17, No. 6, 2004, pp. 432-437. doi:10.1111/j.0894-0959.2004.17603.x
[51] B. L. Sprague, A. Trentham-Dietz, B. E. Klein, R. Klein, K. J. Cruickshanks, K. E. Lee and J. M. Hampton, “Physical Activity, White Blood Cell Count, and Lung Cancer Risk in a Prospective Cohort Study,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 17, No. 10, 2008, pp. 2714-2722. doi:10.1158/1055-9965.EPI-08-0042
[52] Y. H. Li, S. H. Shieh and C. Y. Chen, “The Influence of Health Behaviors on Survival in Lung Cancer Patients in Taiwan,” Japanese Journal of Clinical Oncology, Vol. 41, No. 3, 2011, pp. 365-372. doi:10.1093/jjco/hyq188
[53] T. A. Chiang, P. H. Chen, P. F. Wu, T. N. Wang, P. Y. Chang, A. M. Ko, M. S. Huang and Y. C. Ko, “Important Prognostic Factors for the Long-Term Survival of Lung Cancer Subjects in Taiwan,” BMC Cancer, Vol. 8, No. 324, 2008.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.